Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy for Management of Peritoneal Sarcomatosis: A Preliminary Single-Center Experience from Saudi Arabia

Table 1

Preoperative details of patients.

Variable	(%)
Median age ± SD (range)	46 ± 10.9 (19–57)
Median ECOG performance status score ± SD (range)	1 ± 0.6 (0–2)
Gender
Male	9 (81.8%)
Female	2 (18.2%)
PS presentation
Primary (first disease)	4 (36.4)
Secondary (recurrent disease)	7 (63.6)
Site of origin
Abdominal/pelvic	9 (81.8)
Extra-abdominal/pelvic	2 (18.2)
Both cases were liposarcomas from lower limb, specifically thigh and calf muscles
Histology (pathology)
Retroperitoneal liposarcomas	7 (63.6)
Retroperitoneal non-liposarcomas	4 (36.4)
Leiomyosarcoma	1 (9.1)
Ewing’s Sarcoma	1 (9.1)
GIST (fundus and body origins)	2 (18.2)
Previous treatment
Surgery	7 (63.6)
Radiotherapy	2 (18.2)
Chemotherapy	4 (36.4)
Symptoms
Asymptomatic	1 (9.1)
Flank pain	2 (18.2)
Abdominal pain	8 (72.7)
Increased abdominal circumference	2 (18.2)
Early satiety, nausea, and vomiting	2 (18.2)
Weight loss	3 (27.3)

SD: standard deviation; PS: peritoneal sarcomatosis; ECOG: Eastern Cooperative Oncology Group; GIST: gastrointestinal stromal tumor.